Global strategy for the diagnosis and management of acute kidney injury in patients with liver cirrhosis

1. Kellum, JA, Lameire, N, Aspelin, P, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2: 1–138.
Google Scholar2. Chertow, GM, Burdick, E, Honour, M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365–3370.
Google Scholar | Crossref | Medline | ISI3. Arroyo, V, Ginès, P, Gerbes, AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164–176.
Google Scholar | Crossref | Medline | ISI4. Salerno, F, Gerbes, A, Ginès, P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310–1318.
Google Scholar | Medline | ISI5. Piano, S, Rosi, S, Maresio, G, et al. Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol 2013; 59: 482–489.
Google Scholar | Crossref | Medline6. Huelin, P, Piano, S, Solà, E, et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2017; 15: 438–445.e5.
Google Scholar | Medline7. Angeli, P, Ginès, P, Wong, F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015; 62: 968–974.
Google Scholar | Crossref | Medline8. Ginès, P, Solà, E, Angeli, P, et al. Hepatorenal syndrome. Nat Rev Dis Primer 2018; 4: 23.
Google Scholar | Crossref | Medline9. Amathieu, R, Al-Khafaji, A, Sileanu, FE, et al. Significance of oliguria in critically ill patients with chronic liver disease. Hepatol Baltim Md 2017; 66: 1592–1600.
Google Scholar | Crossref | Medline10. Tandon, P, James, MT, Abraldes, JG, et al. Relevance of new definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: a retrospective population-based cohort study. PloS One 2016; 11: e0160394.
Google Scholar | Crossref | Medline11. Francoz, C, Glotz, D, Moreau, R, et al. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010; 52: 605–613.
Google Scholar | Crossref | Medline | ISI12. Beben, T, Rifkin, DE. GFR estimating equations and liver disease. Adv Chronic Kidney Dis 2015; 22: 337–342.
Google Scholar | Crossref | Medline13. Francoz, C, Prié, D, Abdelrazek, W, et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2010; 16: 1169–1177.
Google Scholar14. Yoo, J-J, Kim, SG, Kim, YS, et al. Estimation of renal function in patients with liver cirrhosis: impact of muscle mass and sex. J Hepatol 2019; 70: 847–854.
Google Scholar | Crossref | Medline15. Hooda, V, Gahlaut, A, Gothwal, A, et al. Bilirubin enzyme biosensor: potentiality and recent advances towards clinical bioanalysis. Biotechnol Lett 2017; 39: 1453–1462.
Google Scholar | Crossref | Medline16. Francoz, C, Nadim, MK, Baron, A, et al. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatol Baltim Md 2014; 59: 1514–1521.
Google Scholar | Crossref | Medline17. Kalafateli, M, Wickham, F, Burniston, M, et al. Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: the Royal Free Hospital cirrhosis glomerular filtration rate. Hepatol Baltim Md 2017; 65: 582–591.
Google Scholar | Crossref | Medline18. Huelin, P, Solà, E, Elia, C, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatol Baltim Md 2019; 70: 319–333.
Google Scholar | Medline19. Russ, KB, Stevens, TM, Singal, AK. Acute kidney injury in patients with cirrhosis. J Clin Transl Hepatol 2015; 3: 195–204.
Google Scholar | Crossref | Medline20. Simonetto, DA, Gines, P, Kamath, PS. Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ 2020; 370.
Google Scholar | Crossref | Medline21. Allegretti, AS, Ortiz, G, Wenger, J, et al. Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: a prospective cohort study. Int J Nephrol 2015; 2015: 108139.
Google Scholar | Crossref | Medline22. Desanti De Oliveira, B, Xu, K, Shen, TH, et al. Molecular nephrology: types of acute tubular injury. Nat Rev Nephrol 2019; 15: 599–612.
Google Scholar | Crossref | Medline23. Angeli, P, Garcia-Tsao, G, Nadim, MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol 2019; 71: 811–822.
Google Scholar | Crossref | Medline24. Alsaad, AA, Wadei, HM. Fractional excretion of sodium in hepatorenal syndrome: clinical and pathological correlation. World J Hepatol 2016; 8: 1497–1501.
Google Scholar | Crossref | Medline25. Wong, F, Angeli, P. New diagnostic criteria and management of acute kidney injury. J Hepatol 2017; 66: 860–861.
Google Scholar | Crossref | Medline26. Fernández, J, Angeli, P, Trebicka, J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2020; 18: 963–973.e14.
Google Scholar | Medline27. Wong, F. Acute kidney injury in liver cirrhosis: new definition and application. Clin Mol Hepatol 2016; 22: 415–422.
Google Scholar | Crossref | Medline28. Davenport, A, Argawal, B, Wright, G, et al. Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis? World J Hepatol 2013; 5: 433–438.
Google Scholar | Crossref | Medline29. Nadim, MK, Durand, F, Kellum, JA, et al. Management of the critically ill patient with cirrhosis: a multidisciplinary perspective. J Hepatol 2016; 64: 717–735.
Google Scholar | Crossref | Medline30. Rhodes, A, Evans, LE, Alhazzani, W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 2017; 45: 486–552.
Google Scholar | Crossref | Medline31. Piano, S, Brocca, A, Angeli, P. Renal function in cirrhosis: a critical review of available tools. Semin Liver Dis 2018; 38: 230–241.
Google Scholar | Crossref | Medline32. Sanchez, LO, Gustot, T. Multidrug-resistant bacterial infection in patients with cirrhosis. A review. Curr Hepatol Rep 2019; 18: 28–35.
Google Scholar | Crossref33. Cavallin, M, Kamath, PS, Merli, M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatol Baltim Md 2015; 62: 567–574.
Google Scholar | Crossref | Medline34. Solanki, P, Chawla, A, Garg, R, et al. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003; 18: 152–156.
Google Scholar | Crossref | Medline | ISI35. Neri, S, Pulvirenti, D, Malaguarnera, M, et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig Dis Sci 2008; 53: 830–835.
Google Scholar | Crossref | Medline | ISI36. Martín-Llahí, M, Guevara, M, Torre, A, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488–496.e4.
Google Scholar | Crossref | Medline37. Sanyal, AJ, Boyer, T, Garcia-Tsao, G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360–1368.
Google Scholar | Crossref | Medline | ISI38. Boyer, TD, Sanyal, AJ, Wong, F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology 2016; 150: 1579–1589.e2.
Google Scholar | Crossref | Medline39. Cavallin, M, Fasolato, S, Marenco, S, et al. The treatment of hepatorenal syndrome. Dig Dis Basel Switz 2015; 33: 548–554.
Google Scholar | Crossref | Medline40. Facciorusso, A, Chandar, AK, Murad, MH, et al. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2017; 2: 94–102.
Google Scholar | Crossref | Medline41. Arora, V, Maiwall, R, Rajan, V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology 2020; 71: 600–610.
Google Scholar | Crossref | Medline42. Gluud, LL, Christensen, K, Christensen, E, et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatol Baltim Md. 2010; 51: 576–584.
Google Scholar | Crossref | Medline | ISI43. Cavallin, M, Piano, S, Romano, A, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatol Baltim Md. 2016; 63: 983–992.
Google Scholar | Crossref | Medline44. Piano, S, Schmidt, HH, Ariza, X, et al. Impact of acute-on-chronic liver failure on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome. J Hepatol 2017; 66: S572.
Google Scholar | Crossref45. Brensing, KA, Textor, J, Perz, J, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288–295.
Google Scholar | Crossref | Medline | ISI46. Staufer, K, Roedl, K, Kivaranovic, D, et al. Renal replacement therapy in critically ill liver cirrhotic patients – outcome and clinical implications. Liver Int 2017; 37: 843–850.
Google Scholar | Crossref | Medline47. Utako, P, Emyoo, T, Anothaisintawee, T, et al. Clinical outcomes after liver transplantation for hepatorenal syndrome: a systematic review and meta-analysis. BioMed Res Int Hindawi 2018; e5362810.
Google Scholar48. Wong, F, Leung, W, Beshir, MA, et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl 2015; 21: 300–307.
Google Scholar | Crossref | Medline49. Chok, KSH, Fung, JYY, Chan, SC, et al. Outcomes of living donor liver transplantation for patients with preoperative type 1 hepatorenal syndrome and acute hepatic decompensation. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc 2012; 18: 779–785.
Google Scholar50. Guevara, M, Fernández-Esparrach, G, Alessandria, C, et al. Effects of contrast media on renal function in patients with cirrhosis: a prospective study. Hepatol Baltim Md. 2004; 40: 646–651.
Google Scholar |

留言 (0)

沒有登入
gif